Fate Therapeutics to Present at Upcoming June Investor Conferences
May 31 2023 - 8:00AM
Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”)
(NASDAQ: FATE), a clinical-stage biopharmaceutical company
dedicated to bringing a first-in-class pipeline of induced
pluripotent stem cell (iPSC)-derived cellular immunotherapies to
patients with cancer and autoimmune disorders, today announced that
the Company will participate in the following upcoming investor
conferences:
- 2023 Jefferies Healthcare Conference on Wednesday, June 7, 2023
at 3:30 PM ET in New York, New York
- 44th Annual Goldman Sachs Global Healthcare Conference on
Tuesday, June 13, 2023 at 5:00 PM ET in Dana Point, California
A live webcast, if recorded, of each presentation can be
accessed under “Events & Presentations” in the Investors
section of the Company’s website at www.fatetherapeutics.com. The
archived webcast will be available on the Company’s website shortly
after the event.
About Fate Therapeutics, Inc.
Fate Therapeutics is a clinical-stage biopharmaceutical company
dedicated to bringing a first-in-class pipeline of induced
pluripotent stem cell (iPSC)-derived cellular immunotherapies to
patients with cancer and autoimmune disorders. Using its
proprietary iPSC product platform, the Company has established a
leadership position in creating multiplexed-engineered iPSC lines
and in the manufacture and clinical development of off-the-shelf,
iPSC-derived cell products. The Company’s effector cell pipeline
includes multiplexed-engineered, iPSC-derived natural killer (NK)
cell and T-cell product candidates, which incorporate novel
synthetic controls of cell function, such as chimeric antigen
receptors (CARs) to target tumor-associated antigens, and are
intended to deliver multiple mechanisms of therapeutic importance
to patients including in combination with well-established cancer
therapies. Fate Therapeutics is headquartered in San Diego, CA. For
more information, please visit www.fatetherapeutics.com.
Contact:Christina TartagliaStern Investor
Relations, Inc.212.362.1200christina.tartaglia@sternir.com
Fate Therapeutics (NASDAQ:FATE)
Historical Stock Chart
From Aug 2024 to Sep 2024
Fate Therapeutics (NASDAQ:FATE)
Historical Stock Chart
From Sep 2023 to Sep 2024